1. 1138PDFirst in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. (23rd October 2018) Authors: Hansen, A; Bauer, T M; Moreno, V; Maio, M; Groenland, S; Martin-Liberal, J; Gan, H; Rischin, D; Millward, M; Olszanski, A J; Cho, D C; Paul, E; Ballas, M; Ellis, C; Zhou, H; Yadavilli, S; Sadik Shaik, J; Schmidt, E V; Hoos, A; Angevin, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 70OA phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors. (17th December 2018) Authors: Deva, S; Lee, J-S; Lin, C-C; Yen, C-J; Millward, M; Chao, Y; Keam, B; Jameson, M; Hou, M-M; Kang, Y-K; Markman, B; Lu, C-H; Rau, K-M; Lee, K-H; Horvath, L; Friedlander, M; Hill, A; Wu, J; Hou, J; Desai, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA14Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy. (24th November 2019) Authors: Abed, A; Khattak, A; Millward, M; Chopra, A; Gray, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (13th August 2019) Authors: Long, G V; Flaherty, K T; Stroyakovskiy, D; Gogas, H; Levchenko, E; de Braud, F; Larkin, J; Garbe, C; Jouary, T; Hauschild, A; Chiarion-Sileni, V; Lebbe, C; Mandalá, M; Millward, M; Arance, A; Bondarenko, I; Haanen, J B A G; Hansson, J; Utikal, J; Ferraresi, V Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1848 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 94O Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data. (15th December 2019) Authors: Gao, B; Goh, J; Markman, B; Voskoboynik, M; Gan, H K; Coward, J; Palmieri, D; So, J; Meniawy, T; Chen, C; Xiang, X; Qiu, J; Xu, Y; Yang, L; Millward, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗